Aisha Vadhariya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aisha Vadhariya has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Deborah A. Fisher
Eli Lilly and Company, Indianapolis, Indiana, USA
3 shared publications - Millie D. Long
Division of Gastroenterology and Hepatology, University of North Carolina , Chapel Hill, NC
3 shared publications - Alison Potts Bleakman
Eli Lilly and Company, Indianapolis, Indiana, USA
2 shared publications Ariane K. Kawata
Evidera, Bethesda, USA
2 shared publicationsClaudine Clucas
Evidera, London, UK
2 shared publicationsFrederick Durand
Eli Lilly and Company, Indianapolis, USA
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study
Background: Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn’s disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two years. Methods: Patients from VIVID-1 with an endoscopic response continued mirikizumab (300 mg subcutaneous) in VIVID-2. Endoscopic non-responders at 52 weeks underwent re-induction, then maintenance therapy. QoL was assessed at Weeks 64 and/or 104 using the Inflammatory Bowel Disease Questionnaire (IBDQ), EQ-5D-5L visual analog scale (VAS), and work productivity by Work Productivity and Activity Impairment: Crohn’s Disease (WPAI:CD) questionnaire. Other patient-reported outcomes (PRO) assessed were fatigue (FACIT-Fatigue), abdominal pain (AP), stool frequency (SF), and clinical remission by PRO (AP ≤1 and SF ≤3, no worsening from baseline). Missing data were handled with modified non-responder imputation for categorical outcomes, and baseline observation carried forward for continuous outcomes. Analysis of covariance was used to estimate mean changes from baseline. Results: At 104 weeks, 85.0% of VIVID-1 endoscopic responders and 72.6% endoscopic non-responders achieved IBDQ response, while 71.3% endoscopic responders and 60.8% endoscopic non-responders achieved IBDQ remission. By Week 64, EQ-5D-5L VAS scores improved by 22–27 points, WPAI decreased by 14–34 points, and >60% patients achieved meaningful improvement in fatigue. Approximately 75% responders and 54% non-responders achieved clinical remission by PRO at two years. Conclusion: Long-term mirikizumab treatment led to sustained QoL improvements and reduced symptoms in patients with CD, regardless of their endoscopic response status.
- 14 October 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Open AccessLong-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study
Background: Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn’s disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two years. Methods: Patients from VIVID-1 with an endoscopic response continued mirikizumab (300 mg subcutaneous) in VIVID-2. Endoscopic non-responders at 52 weeks underwent re-induction, then maintenance therapy. QoL was assessed at Weeks 64 and/or 104 using the Inflammatory Bowel Disease Questionnaire (IBDQ), EQ-5D-5L visual analog scale (VAS), and work productivity by Work Productivity and Activity Impairment: Crohn’s Disease (WPAI:CD) questionnaire. Other patient-reported outcomes (PRO) assessed were fatigue (FACIT-Fatigue), abdominal pain (AP), stool frequency (SF), and clinical remission by PRO (AP ≤1 and SF ≤3, no worsening from baseline). Missing data were handled with modified non-responder imputation for categorical outcomes, and baseline observation carried forward for continuous outcomes. Analysis of covariance was used to estimate mean changes from baseline. Results: At 104 weeks, 85.0% of VIVID-1 endoscopic responders and 72.6% endoscopic non-responders achieved IBDQ response, while 71.3% endoscopic responders and 60.8% endoscopic non-responders achieved IBDQ remission. By Week 64, EQ-5D-5L VAS scores improved by 22–27 points, WPAI decreased by 14–34 points, and >60% patients achieved meaningful improvement in fatigue. Approximately 75% responders and 54% non-responders achieved clinical remission by PRO at two years. Conclusion: Long-term mirikizumab treatment led to sustained QoL improvements and reduced symptoms in patients with CD, regardless of their endoscopic response status.
- Open Access
- 24 September 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (4) , otag107
Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial
Background: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody approved for ulcerative colitis (UC) and Crohn’s disease, was evaluated in LUCENT-URGE (NCT05767021), a phase 3b, open-label study assessing its effect on bowel urgency (BU) through week (W)28 in adults with moderately-to-severely active UC, using novel BU measures and validated quality of life (QoL) instruments. Methods: Patients with UC experiencing BU (baseline severity ≥3 on the urgency numeric rating scale [UNRS]) received 300 mg mirikizumab intravenously at W0, W4, and W8, then 200 mg subcutaneously at W12 and every 4 weeks up to W24. Improvements in QoL and patient-reported outcomes were assessed from baseline to W12 and W28. Results: Among 172 patients, 58.1% achieved clinically meaningful improvement (≥3-point reduction in UNRS), and 37.8% reached BU remission (rounded UNRS ≤ 1) by W28. Inflammatory Bowel Disease Questionnaire (IBDQ) scores improved by 56.4 points, with 52.3% of patients achieving IBDQ-remission (IBDQ ≥ 170) and 65.7% achieving IBDQ-response (≥16-point increase) at W28. Absorbent product use for BU dropped from 55.1% at baseline to 29.6% at W28. Patients reporting no sexual activity avoidance (SAA) due to UC symptoms rose from 21.1% to 51.4%. Activity impairment, Wexner Incontinence Score, and anxiety symptoms also showed improvements. Conclusion: The majority of mirikizumab-treated patients achieved clinically meaningful BU improvement over 28 weeks. In addition to QoL improvement, patients experienced reduced disruption of daily activities, with meaningful reductions in SAA and use of protective aids due to BU. Achieving BU remission or clinically meaningful improvement with mirikizumab was associated with improvements in patients’ relevant UC symptoms and overall QoL.
- 24 September 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (4) , otag107
Open AccessMirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial
Background: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody approved for ulcerative colitis (UC) and Crohn’s disease, was evaluated in LUCENT-URGE (NCT05767021), a phase 3b, open-label study assessing its effect on bowel urgency (BU) through week (W)28 in adults with moderately-to-severely active UC, using novel BU measures and validated quality of life (QoL) instruments. Methods: Patients with UC experiencing BU (baseline severity ≥3 on the urgency numeric rating scale [UNRS]) received 300 mg mirikizumab intravenously at W0, W4, and W8, then 200 mg subcutaneously at W12 and every 4 weeks up to W24. Improvements in QoL and patient-reported outcomes were assessed from baseline to W12 and W28. Results: Among 172 patients, 58.1% achieved clinically meaningful improvement (≥3-point reduction in UNRS), and 37.8% reached BU remission (rounded UNRS ≤ 1) by W28. Inflammatory Bowel Disease Questionnaire (IBDQ) scores improved by 56.4 points, with 52.3% of patients achieving IBDQ-remission (IBDQ ≥ 170) and 65.7% achieving IBDQ-response (≥16-point increase) at W28. Absorbent product use for BU dropped from 55.1% at baseline to 29.6% at W28. Patients reporting no sexual activity avoidance (SAA) due to UC symptoms rose from 21.1% to 51.4%. Activity impairment, Wexner Incontinence Score, and anxiety symptoms also showed improvements. Conclusion: The majority of mirikizumab-treated patients achieved clinically meaningful BU improvement over 28 weeks. In addition to QoL improvement, patients experienced reduced disruption of daily activities, with meaningful reductions in SAA and use of protective aids due to BU. Achieving BU remission or clinically meaningful improvement with mirikizumab was associated with improvements in patients’ relevant UC symptoms and overall QoL.
- 1 March 2026
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 32 (3) , 348-359
Biologic dose escalation in inflammatory bowel disease in the United States
Treatment for inflammatory bowel disease (IBD), composed of Crohn disease (CD) and ulcerative colitis (UC), frequently employs biologics to help control inflammation, reduce symptom burden, and limit disease progression. Because of both the lifelong, progressive nature of disease and potential for loss of therapy response over time, therapy changes are common. Biologic dose escalation is one method to adjust therapy regimens following loss of response. To assess the occurrence of dose escalation in CD and UC and its influence on health care costs. Adults with a diagnosis of CD or UC newly initiating therapy with a biologic (adalimumab, infliximab, ustekinumab, vedolizumab, or tofacitinib [UC only]) from January 1, 2017, to June 30, 2022, were selected in the Merative MarketScan Commercial and Medicare Databases. The first claim for the biologic served as the index date and patients were followed over a 12-month pre-period and a 12-month-or-longer post-period. Dose escalation during the maintenance phase of therapy, discontinuation, and postdiscontinuation switching were assessed in biologic-based subgroups in each of the CD and UC cohorts; per-patient-per-month (PPPM) IBD-related health care costs over the duration of index biologic treatment were also calculated. Analyses included 6,056 patients with CD (33.5% adalimumab, 30.6% ustekinumab, 18.8% infliximab, 17.1% vedolizumab) and 4,533 patients with UC (35.1% vedolizumab, 30.6% adalimumab, 16.8% infliximab, 10.0% ustekinumab, 7.5% tofacitinib). Dose escalation occurred in 30.4% of patients with CD (adalimumab 20.8%, infliximab 48.8%, ustekinumab 26.9%, vedolizumab 36.2%) and 30.1% of patients with UC (adalimumab 23.0%, infliximab 44.8%, ustekinumab 25.5%, vedolizumab 31.8%, tofacitinib 24.9%). Patients with evidence of dose escalation had lower rates of discontinuation compared with nonescalators over follow-up but were more likely to switch biologics after discontinuation. PPPM IBD-related health care costs over the course of treatment were substantial and largely driven by index biologic costs. Mean PPPM costs for the CD cohort ranged from $4,543 in the infliximab group to $14,031 in the ustekinumab group; costs were similar in the UC cohort, ranging from $5,213 in the infliximab group to $14,246 in the ustekinumab group. Within both cohorts, dose escalation was a significant predictor of increased IBD-related health care costs. Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.
- 1 March 2026
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 32 (3) , 348-359
Biologic dose escalation in inflammatory bowel disease in the United States
Treatment for inflammatory bowel disease (IBD), composed of Crohn disease (CD) and ulcerative colitis (UC), frequently employs biologics to help control inflammation, reduce symptom burden, and limit disease progression. Because of both the lifelong, progressive nature of disease and potential for loss of therapy response over time, therapy changes are common. Biologic dose escalation is one method to adjust therapy regimens following loss of response. To assess the occurrence of dose escalation in CD and UC and its influence on health care costs. Adults with a diagnosis of CD or UC newly initiating therapy with a biologic (adalimumab, infliximab, ustekinumab, vedolizumab, or tofacitinib [UC only]) from January 1, 2017, to June 30, 2022, were selected in the Merative MarketScan Commercial and Medicare Databases. The first claim for the biologic served as the index date and patients were followed over a 12-month pre-period and a 12-month-or-longer post-period. Dose escalation during the maintenance phase of therapy, discontinuation, and postdiscontinuation switching were assessed in biologic-based subgroups in each of the CD and UC cohorts; per-patient-per-month (PPPM) IBD-related health care costs over the duration of index biologic treatment were also calculated. Analyses included 6,056 patients with CD (33.5% adalimumab, 30.6% ustekinumab, 18.8% infliximab, 17.1% vedolizumab) and 4,533 patients with UC (35.1% vedolizumab, 30.6% adalimumab, 16.8% infliximab, 10.0% ustekinumab, 7.5% tofacitinib). Dose escalation occurred in 30.4% of patients with CD (adalimumab 20.8%, infliximab 48.8%, ustekinumab 26.9%, vedolizumab 36.2%) and 30.1% of patients with UC (adalimumab 23.0%, infliximab 44.8%, ustekinumab 25.5%, vedolizumab 31.8%, tofacitinib 24.9%). Patients with evidence of dose escalation had lower rates of discontinuation compared with nonescalators over follow-up but were more likely to switch biologics after discontinuation. PPPM IBD-related health care costs over the course of treatment were substantial and largely driven by index biologic costs. Mean PPPM costs for the CD cohort ranged from $4,543 in the infliximab group to $14,031 in the ustekinumab group; costs were similar in the UC cohort, ranging from $5,213 in the infliximab group to $14,246 in the ustekinumab group. Within both cohorts, dose escalation was a significant predictor of increased IBD-related health care costs. Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.
- Open Access
- 21 November 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00953
Geographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States
INTRODUCTION: We aimed to map the distribution of patients with inflammatory bowel disease (IBD) and gastroenterologists throughout the United States and identify local-level and state-level variations in the availability of specialist care. METHODS: For each first 3-digit ZIP code tabulation area (ZCTA) and state in the United States, we calculated the density of patients with IBD (Crohn's disease or ulcerative colitis) per 100,000 population, gastroenterologists per 100,000 population, and gastroenterologists per 100 patients with IBD. We used 2022 claims data to identify patients with IBD, the 2022 National Provider Identifier registry for provider details, and the 2020 US Census for area-level variables. RESULTS: Overall, 520,020 patients with IBD and 21,611 gastroenterologists were identified. Patient density varied across states, from 58.2 (New Mexico) to 337.1 (Maine). On average, there were 4.2 (ranging from 1.4 in Kansas to 9.8 in Hawaii) gastroenterologists/100 patients with IBD. The Midwest and the Southwest Border regions had the lowest density of gastroenterologists. Across the United States, 130 3-digit ZIP code tabulation areas (ZCTA) had zero gastroenterologists/100 patients; 62% of these ZIP codes were in rural areas, and 25% had household income <150% of the poverty line. ZIP codes with ≥5 gastroenterologists/100,000 population tended to have lower poverty rates and were more urban than those with 1 to <5 gastroenterologists/100,000 population. DISCUSSION: Geographic disparities in the availability of gastroenterologist care exist at the state and local levels. This disparity was highlighted for patients with IBD and populations living in rural and high-poverty areas.
- 21 November 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00953
Open AccessGeographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States
INTRODUCTION: We aimed to map the distribution of patients with inflammatory bowel disease (IBD) and gastroenterologists throughout the United States and identify local-level and state-level variations in the availability of specialist care. METHODS: For each first 3-digit ZIP code tabulation area (ZCTA) and state in the United States, we calculated the density of patients with IBD (Crohn's disease or ulcerative colitis) per 100,000 population, gastroenterologists per 100,000 population, and gastroenterologists per 100 patients with IBD. We used 2022 claims data to identify patients with IBD, the 2022 National Provider Identifier registry for provider details, and the 2020 US Census for area-level variables. RESULTS: Overall, 520,020 patients with IBD and 21,611 gastroenterologists were identified. Patient density varied across states, from 58.2 (New Mexico) to 337.1 (Maine). On average, there were 4.2 (ranging from 1.4 in Kansas to 9.8 in Hawaii) gastroenterologists/100 patients with IBD. The Midwest and the Southwest Border regions had the lowest density of gastroenterologists. Across the United States, 130 3-digit ZIP code tabulation areas (ZCTA) had zero gastroenterologists/100 patients; 62% of these ZIP codes were in rural areas, and 25% had household income <150% of the poverty line. ZIP codes with ≥5 gastroenterologists/100,000 population tended to have lower poverty rates and were more urban than those with 1 to <5 gastroenterologists/100,000 population. DISCUSSION: Geographic disparities in the availability of gastroenterologist care exist at the state and local levels. This disparity was highlighted for patients with IBD and populations living in rural and high-poverty areas.
- Open Access
- 19 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1082-1093
Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers
Bowel urgency (BU) is a prevalent and highly burdensome symptom among patients with inflammatory bowel disease. While BU is now recognized as a key symptom of ulcerative colitis, in the case of Crohn's disease (CD), it is often under-recognized by healthcare providers (HCPs) and inadequately captured in clinical assessments. Reported in up to 96% of patients with CD, BU can significantly impair quality of life, contributing to anxiety, social withdrawal, and reduced daily functioning. Despite its frequency and impact, BU is excluded from widely used CD activity indices and is infrequently included in clinical trial end points. An important challenge in the management of CD is the differing perceptions between patients and HCPs regarding the impact and importance of BU. This disconnect between patients and HCPs may lead to gaps in treatment and unmet patient needs. This narrative review synthesizes recent evidence on the prevalence, clinical significance, and underlying mechanisms of BU in CD. We also examine its impact on quality of life, evaluate current assessment tools, and highlight therapeutic approaches and gaps in HCP-patient communication. Greater awareness and systematic evaluation of BU as a multidimensional symptom of CD are critical for optimizing care and aligning clinical management with patient priorities.
- 19 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1082-1093
Open AccessBowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers
Bowel urgency (BU) is a prevalent and highly burdensome symptom among patients with inflammatory bowel disease. While BU is now recognized as a key symptom of ulcerative colitis, in the case of Crohn's disease (CD), it is often under-recognized by healthcare providers (HCPs) and inadequately captured in clinical assessments. Reported in up to 96% of patients with CD, BU can significantly impair quality of life, contributing to anxiety, social withdrawal, and reduced daily functioning. Despite its frequency and impact, BU is excluded from widely used CD activity indices and is infrequently included in clinical trial end points. An important challenge in the management of CD is the differing perceptions between patients and HCPs regarding the impact and importance of BU. This disconnect between patients and HCPs may lead to gaps in treatment and unmet patient needs. This narrative review synthesizes recent evidence on the prevalence, clinical significance, and underlying mechanisms of BU in CD. We also examine its impact on quality of life, evaluate current assessment tools, and highlight therapeutic approaches and gaps in HCP-patient communication. Greater awareness and systematic evaluation of BU as a multidimensional symptom of CD are critical for optimizing care and aligning clinical management with patient priorities.
- Open Access
- 13 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (8) , 1809-1819
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
INTRODUCTION: Mirikizumab demonstrated significant efficacy compared with placebo in patients with Crohn's disease (CD) in the phase 3 VIVID-1 study. In this study, we report the impact of mirikizumab vs placebo on health-related quality of life (HRQoL) and work productivity in VIVID-1. METHODS: VIVID-1 patients randomized to receive mirikizumab (N = 579), or placebo (N = 199) were included. The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 Health Survey (SF-36), EQ-5D-5L visual analog scale, and Work Productivity and Activity Impairment: CD measures. The Cochran-Mantel-Haenszel test with nonresponder imputation (binary end points) and analysis of covariance with modified baseline observation carried forward (continuous end points) were used for treatment comparisons. RESULTS: Greater improvements in the mean change from baseline to weeks 12 and 52 were observed with mirikizumab vs placebo in IBDQ total and domain scores, SF-36 summary and domain scores, and EQ-5D-5L visual analog scale scores (all P < 0.001). Significant improvements with mirikizumab vs placebo were observed in Work Productivity and Activity Impairment:CD scores at week 12: absenteeism (P = 0.001), presenteeism (P = 0.005), activity impairment (P < 0.001), and overall work impairment (P = 0.002); these improvements were maintained at week 52 (all P < 0.001, except absenteeism). At weeks 12 and 52, a greater proportion of mirikizumab-treated patients vs placebo achieved IBDQ response, IBDQ remission, and clinically important improvement in physical and mental component summaries of SF-36 (all P < 0.001). DISCUSSION: Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52.
- 13 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (8) , 1809-1819
Open AccessMirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
INTRODUCTION: Mirikizumab demonstrated significant efficacy compared with placebo in patients with Crohn's disease (CD) in the phase 3 VIVID-1 study. In this study, we report the impact of mirikizumab vs placebo on health-related quality of life (HRQoL) and work productivity in VIVID-1. METHODS: VIVID-1 patients randomized to receive mirikizumab (N = 579), or placebo (N = 199) were included. The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 Health Survey (SF-36), EQ-5D-5L visual analog scale, and Work Productivity and Activity Impairment: CD measures. The Cochran-Mantel-Haenszel test with nonresponder imputation (binary end points) and analysis of covariance with modified baseline observation carried forward (continuous end points) were used for treatment comparisons. RESULTS: Greater improvements in the mean change from baseline to weeks 12 and 52 were observed with mirikizumab vs placebo in IBDQ total and domain scores, SF-36 summary and domain scores, and EQ-5D-5L visual analog scale scores (all P < 0.001). Significant improvements with mirikizumab vs placebo were observed in Work Productivity and Activity Impairment:CD scores at week 12: absenteeism (P = 0.001), presenteeism (P = 0.005), activity impairment (P < 0.001), and overall work impairment (P = 0.002); these improvements were maintained at week 52 (all P < 0.001, except absenteeism). At weeks 12 and 52, a greater proportion of mirikizumab-treated patients vs placebo achieved IBDQ response, IBDQ remission, and clinically important improvement in physical and mental component summaries of SF-36 (all P < 0.001). DISCUSSION: Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52.
- Open Access
- 17 February 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-14
A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn’s Disease Activity Index: psychometric evaluation in adults with Crohn’s disease
Background: The Stool Frequency (SF) and Abdominal Pain (AP) items from the Crohn’s Disease Activity Index are together referred to as the “Patient Reported Outcome” (PRO). The SF item measures the number of very soft/liquid stools and the AP item measures abdominal pain severity, which are common Crohn’s disease (CD) symptoms that patients consider important to treat. This study evaluated the psychometric properties of both PRO items separately and estimated thresholds for clinical remission in moderately to severely active CD. Methods: The measurement properties of the PRO items were analyzed using pooled data from VIVID-1 (NCT03926130), a Phase 3, randomized, placebo- and active-controlled study in adults with moderately to severely active CD. Analyses used weekly average scores of the SF and AP items at Weeks 0 (Baseline), 4, 12, and 52. Remission thresholds were estimated using the Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) as primary anchors as well as qualitative evidence from exit interviews. Results: Data from 1065 participants (mean age: 36.2 years [standard deviation: 13 years]) were analyzed. During the trial, scores improved for both PRO items. Both items demonstrated moderate-to-good test-retest reliability for participants defined as stable based on PGRS and PGIC. Most correlations of related assessments were moderate (0.30≤|ρ| | ≤0.90) with AP. By contrast, as anticipated, both items had weak correlations (|ρ| <0.30) with endoscopic and laboratory assessments. The PRO items could discriminate between groups of participants known to differ based on other assessments. The PRO items were able to detect change, as score changes in both items between Baseline and Weeks 12 and 52 differed significantly between most PGRS and PGIC categories. Anchor-based analyses combined with responses from the exit interviews suggested that an SF score of ≤ 3 and an AP score of ≤ 1 could together represent clinical remission. Conclusion: These results support the reliability, construct-validity, and responsiveness of both PRO items in moderately to severely active CD and confirm previously suggested scores for both items that could represent clinical remission. Trial registration: Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.
- 17 February 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-14
Open AccessA patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn’s Disease Activity Index: psychometric evaluation in adults with Crohn’s disease
Background: The Stool Frequency (SF) and Abdominal Pain (AP) items from the Crohn’s Disease Activity Index are together referred to as the “Patient Reported Outcome” (PRO). The SF item measures the number of very soft/liquid stools and the AP item measures abdominal pain severity, which are common Crohn’s disease (CD) symptoms that patients consider important to treat. This study evaluated the psychometric properties of both PRO items separately and estimated thresholds for clinical remission in moderately to severely active CD. Methods: The measurement properties of the PRO items were analyzed using pooled data from VIVID-1 (NCT03926130), a Phase 3, randomized, placebo- and active-controlled study in adults with moderately to severely active CD. Analyses used weekly average scores of the SF and AP items at Weeks 0 (Baseline), 4, 12, and 52. Remission thresholds were estimated using the Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) as primary anchors as well as qualitative evidence from exit interviews. Results: Data from 1065 participants (mean age: 36.2 years [standard deviation: 13 years]) were analyzed. During the trial, scores improved for both PRO items. Both items demonstrated moderate-to-good test-retest reliability for participants defined as stable based on PGRS and PGIC. Most correlations of related assessments were moderate (0.30≤|ρ| | ≤0.90) with AP. By contrast, as anticipated, both items had weak correlations (|ρ| <0.30) with endoscopic and laboratory assessments. The PRO items could discriminate between groups of participants known to differ based on other assessments. The PRO items were able to detect change, as score changes in both items between Baseline and Weeks 12 and 52 differed significantly between most PGRS and PGIC categories. Anchor-based analyses combined with responses from the exit interviews suggested that an SF score of ≤ 3 and an AP score of ≤ 1 could together represent clinical remission. Conclusion: These results support the reliability, construct-validity, and responsiveness of both PRO items in moderately to severely active CD and confirm previously suggested scores for both items that could represent clinical remission. Trial registration: Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.
- Open Access
- 18 December 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (2) , 1044-1060
The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn’s Disease
Introduction Bowel urgency has recently been recognized as a Crohn’s disease (CD) symptom that substantially impacts patients’ quality of life. The Urgency NRS is a single-item patient-reported outcome measure assessing bowel urgency severity in the past 24 h (0–10 scale). We aimed to evaluate the psychometric properties of the Urgency Numeric Rating Scale (NRS) in adults with moderately to severely active CD and to estimate thresholds for meaningful improvement and bowel urgency remission. Methods Psychometric analyses used pooled data from the Phase 3 VIVID-1 study of mirikizumab, where participants with CD completed the Urgency NRS and other assessments. The Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) were used as primary anchors to estimate Urgency NRS thresholds representing meaningful improvement and remission. Results The Urgency NRS showed good test–retest reliability in participants who were stable based on PGRS and PGIC. It was moderately correlated with similar assessments and weakly correlated with endoscopic/laboratory assessments. It differentiated between participant subgroups varying in disease severity and quality of life based on PGRS and other assessments. It was sensitive to change, as Urgency NRS improvements during the trial differed between most PGRS change and PGIC categories. A 3–5-point reduction on the Urgency NRS represented meaningful improvement and a score of ≤ 2 represented remission. Conclusion The Urgency NRS demonstrated strong psychometric properties in the VIVID-1 population of moderately to severely active CD. Analyses also suggested meaningful improvement and remission thresholds. Trial Registration Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.
- 18 December 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (2) , 1044-1060
Open AccessThe Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn’s Disease
Introduction Bowel urgency has recently been recognized as a Crohn’s disease (CD) symptom that substantially impacts patients’ quality of life. The Urgency NRS is a single-item patient-reported outcome measure assessing bowel urgency severity in the past 24 h (0–10 scale). We aimed to evaluate the psychometric properties of the Urgency Numeric Rating Scale (NRS) in adults with moderately to severely active CD and to estimate thresholds for meaningful improvement and bowel urgency remission. Methods Psychometric analyses used pooled data from the Phase 3 VIVID-1 study of mirikizumab, where participants with CD completed the Urgency NRS and other assessments. The Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) were used as primary anchors to estimate Urgency NRS thresholds representing meaningful improvement and remission. Results The Urgency NRS showed good test–retest reliability in participants who were stable based on PGRS and PGIC. It was moderately correlated with similar assessments and weakly correlated with endoscopic/laboratory assessments. It differentiated between participant subgroups varying in disease severity and quality of life based on PGRS and other assessments. It was sensitive to change, as Urgency NRS improvements during the trial differed between most PGRS change and PGIC categories. A 3–5-point reduction on the Urgency NRS represented meaningful improvement and a score of ≤ 2 represented remission. Conclusion The Urgency NRS demonstrated strong psychometric properties in the VIVID-1 population of moderately to severely active CD. Analyses also suggested meaningful improvement and remission thresholds. Trial Registration Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.
- Open Access
- 20 August 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1333-1345
Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative L.P. MarketScan® Claims Databases. This retrospective cohort study included adults with axSpA who initiated ixekizumab during the index period (September 2019-December 2021). Index date was the date of the first ixekizumab claim. All patients had continuous medical and pharmacy enrollment during the 12-month pre-index and follow-up periods. Descriptive statistics were used to assess patient demographics (index date); clinical characteristics (pre-index period); treatment patterns (12-month follow-up period); and HCRU (pre-index and 12-month follow-up periods). The study included 177 patients (mean age 45.8 years; females 54.8%) with axSpA who initiated ixekizumab. Overall, 79.1% of patients reported prior biologic use; of these, 70.7% received tumor necrosis factor-alpha inhibitors (TNFi) and 49% received secukinumab. The mean (standard deviation [SD]) Charlson Comorbidity Index score was 1.1 (1.3) and ~ 27% of patients reported ≥2 comorbidities. The median (inter-quartile range [IQR]) number of ixekizumab prescription refills was 7 (4-11). The mean (SD) Proportion of Days Covered (PDC) for ixekizumab was 0.6 (0.3) and adherence (PDC ≥80%) was 34.5% (N = 61). Overall, 26.6% (N = 47) of patients switched to a non-index medication and 54.2% (N = 96) of patients discontinued ixekizumab. Among the patients who discontinued ixekizumab (N = 96), 19.8% (N = 19) restarted ixekizumab and 49.0% (N = 47) switched to a non-index medication. The median (IQR) ixekizumab persistence was 268 (120-366) days. Mean axSpA-related outpatient, inpatient, and emergency room visits were similar between the pre-index and follow-up periods. Treatment patterns were largely similar between biologic-experienced patients (N = 140; 79.1%) and the overall population. Despite high comorbidity burden and majority of the patients being biologic-experienced, patients initiating ixekizumab for axSpA showed favorable persistence profiles during the 12-month follow-up period.
- 20 August 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1333-1345
Open AccessIxekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative L.P. MarketScan® Claims Databases. This retrospective cohort study included adults with axSpA who initiated ixekizumab during the index period (September 2019-December 2021). Index date was the date of the first ixekizumab claim. All patients had continuous medical and pharmacy enrollment during the 12-month pre-index and follow-up periods. Descriptive statistics were used to assess patient demographics (index date); clinical characteristics (pre-index period); treatment patterns (12-month follow-up period); and HCRU (pre-index and 12-month follow-up periods). The study included 177 patients (mean age 45.8 years; females 54.8%) with axSpA who initiated ixekizumab. Overall, 79.1% of patients reported prior biologic use; of these, 70.7% received tumor necrosis factor-alpha inhibitors (TNFi) and 49% received secukinumab. The mean (standard deviation [SD]) Charlson Comorbidity Index score was 1.1 (1.3) and ~ 27% of patients reported ≥2 comorbidities. The median (inter-quartile range [IQR]) number of ixekizumab prescription refills was 7 (4-11). The mean (SD) Proportion of Days Covered (PDC) for ixekizumab was 0.6 (0.3) and adherence (PDC ≥80%) was 34.5% (N = 61). Overall, 26.6% (N = 47) of patients switched to a non-index medication and 54.2% (N = 96) of patients discontinued ixekizumab. Among the patients who discontinued ixekizumab (N = 96), 19.8% (N = 19) restarted ixekizumab and 49.0% (N = 47) switched to a non-index medication. The median (IQR) ixekizumab persistence was 268 (120-366) days. Mean axSpA-related outpatient, inpatient, and emergency room visits were similar between the pre-index and follow-up periods. Treatment patterns were largely similar between biologic-experienced patients (N = 140; 79.1%) and the overall population. Despite high comorbidity burden and majority of the patients being biologic-experienced, patients initiating ixekizumab for axSpA showed favorable persistence profiles during the 12-month follow-up period.
- Open Access
- 2 July 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1101-1114
Filling the “GAP” in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint
Introduction Some retrospective data sources, such as electronic health records in the USA, report composite outcome measures not fully validated in psoriatic arthritis (PsA). However, they often contain global assessments, such as a Physician Global Assessment (PhGA) and Patient Global Assessment (PatGA), along with patient-reported pain scores, which individually are considered validated in PsA. This research described the performance characteristics of a 3-item global assessment and pain (GAP) composite endpoint using data from the ixekizumab phase 3 PsA clinical trial program. Methods Discrimination of GAP was assessed by comparing placebo to active treatment arms. The magnitude of treatment effect and responsiveness were compared to Disease Activity Index for PsA (DAPSA), clinical DAPSA, DAPSA28, and Psoriatic Arthritis Disease Activity Score (PASDAS) using effect size (ES) and standardized response mean (SRM), respectively. Construct validity was evaluated through correlation among the composite endpoints, and with other physician- and patient-reported outcomes. Change in GAP was compared in patients who reached low disease activity (LDA) levels based on DAPSA, cDAPSA, and PASDAS vs those who did not. Results GAP discriminated between active treatment and placebo with statistically significant separation as early as week 1. The largest ES/SRM was seen with GAP (2.29/1.74) and PASDAS (2.47/1.68). GAP had the strongest correlation with PASDAS (0.81–0.92) and showed moderate correlations with patient-assessed physical function, low correlations with physician-assessed skin and nail psoriasis, and low to moderate correlation with physician-assessed enthesitis. A significantly greater improvement in GAP was seen in the groups achieving LDA states compared to those not (p < 0.001). Conclusion The GAP composite, an abbreviated endpoint comprising measures common in electronic health records, has promising performance characteristics and could be used to address important clinical questions regarding outcomes and impact of PsA in existing datasets. ClinTrials.gov Identifier NCT01695239; NCT02349295.
- 2 July 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1101-1114
Open AccessFilling the “GAP” in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint
Introduction Some retrospective data sources, such as electronic health records in the USA, report composite outcome measures not fully validated in psoriatic arthritis (PsA). However, they often contain global assessments, such as a Physician Global Assessment (PhGA) and Patient Global Assessment (PatGA), along with patient-reported pain scores, which individually are considered validated in PsA. This research described the performance characteristics of a 3-item global assessment and pain (GAP) composite endpoint using data from the ixekizumab phase 3 PsA clinical trial program. Methods Discrimination of GAP was assessed by comparing placebo to active treatment arms. The magnitude of treatment effect and responsiveness were compared to Disease Activity Index for PsA (DAPSA), clinical DAPSA, DAPSA28, and Psoriatic Arthritis Disease Activity Score (PASDAS) using effect size (ES) and standardized response mean (SRM), respectively. Construct validity was evaluated through correlation among the composite endpoints, and with other physician- and patient-reported outcomes. Change in GAP was compared in patients who reached low disease activity (LDA) levels based on DAPSA, cDAPSA, and PASDAS vs those who did not. Results GAP discriminated between active treatment and placebo with statistically significant separation as early as week 1. The largest ES/SRM was seen with GAP (2.29/1.74) and PASDAS (2.47/1.68). GAP had the strongest correlation with PASDAS (0.81–0.92) and showed moderate correlations with patient-assessed physical function, low correlations with physician-assessed skin and nail psoriasis, and low to moderate correlation with physician-assessed enthesitis. A significantly greater improvement in GAP was seen in the groups achieving LDA states compared to those not (p < 0.001). Conclusion The GAP composite, an abbreviated endpoint comprising measures common in electronic health records, has promising performance characteristics and could be used to address important clinical questions regarding outcomes and impact of PsA in existing datasets. ClinTrials.gov Identifier NCT01695239; NCT02349295.